unyango lomhlaza wemiphunga we-metastatic olungelulo oluncinci

Umhlaza wemiphunga we-Metastatic ongeyonto encinci (mNSCLC) sisifo esintsonkothileyo esifuna iindlela zonyango zomntu. Esi sikhokelo sibonelela ngombono weendlela zonyango zamva nje, kubandakanywa unyango olujoliswe kuyo, i-immunotherapy, i-chemotherapy, kunye nezilingo zeklinikhi, ukuxhobisa izigulane kunye neentsapho zabo ngolwazi lokwenza izigqibo ezinolwazi.Ukuqonda i-Metastatic Non-Small Cell Lung CancerUmhlaza wemiphunga weMetastatic ongeyonxalenye encinci, ekwaziwa njengenqanaba le-IV NSCLC, lithetha ukuba umhlaza usasazeke ukusuka kwimiphunga ukuya kwamanye amalungu omzimba. Iindawo eziqhelekileyo ze-metastasis ziquka ingqondo, amathambo, isibindi, kunye namadlala e-adrenal. Ngelixa umhlaza we-metastatic unokuba ngumngeni ngakumbi ukunyanga, ukuqhubela phambili kwiinketho zonyango kuye kwaphucula kakhulu iziphumo kunye nomgangatho wobomi kwizigulane ezininzi. Ukuxilongwa kwangethuba kubalulekile, kwaye unokufunda ngakumbi malunga nophando lomhlaza kwiziko loPhando loMhlaza laseShandong Baofa. Iintlobo zoMhlaza weMiphunga yeSeli engeNcinciZimbini iindidi eziphambili ze-NSCLC yi-adenocarcinoma kunye ne-squamous cell carcinoma. I-Adenocarcinoma lolona hlobo luxhaphakileyo kwaye idla ngokuvela kubantu abangatshayiyo. I-squamous cell carcinoma idla ngokunxulunyaniswa nokutshaya. Ezinye iintlobo ezingaxhaphakanga kakhulu ziquka i-cell carcinoma enkulu kunye ne-adenosquamous carcinoma. Ukuxilongwa ngokuchanekileyo kwe-subtype kubalulekile ekumiseleni eyona ndlela yonyango esebenzayo.Ukuxilongwa kunye ne-StagingDiagnosing unyango lomhlaza wemiphunga we-metastatic olungelulo oluncinci ngokuqhelekileyo kubandakanya indibaniselwano yovavanyo lokucinga (CT scans, PET scans, MRI), biopsies, novavanyo lwemolekyuli. Uvavanyo lwemolekyuli luhlalutya iiseli zomhlaza kwiinguqulelo ezithile zofuzo okanye ii-biomarkers ezinokujoliswa kunyango oluthile. Inqanaba limisela ubungakanani bokunwenwa komhlaza, ukunceda oogqirha balungelelanise isicwangciso sonyango. Iinketho zonyango lweMetastatic Non-Small Cell Lung Cancer Treatment for unyango lomhlaza wemiphunga we-metastatic olungelulo oluncinci ngokuqhelekileyo i-systemic, ithetha ukuba ichaphazela umzimba wonke. Iindlela zonyango eziqhelekileyo zibandakanya: ITherapyTargeted therapy amachiza amachiza ajolise ngokukodwa kwiimolekyuli ezithile (ezifana neeprotheni okanye iijini) ezinceda iiseli zomhlaza ukuba zikhule kwaye zisasazeke. Ezi zonyango zihlala zisetyenziselwa izigulane ezinee-tumors ezine-genetic mutations ezithile.EGFR InhibitorsEpidermal Growth Factor Receptor (EGFR) inhibitors isetyenziselwa izigulane ezine-EGFR mutations. I-EGFR inhibitors eqhelekileyo iquka: i-Osimertinib (Tagrisso) i-Erlotinib (i-Tarceva) i-Gefitinib (i-Iressa) i-Afatinib (i-Gilotrif)La mayeza avimbela iprotheni ye-EGFR, ukuthintela iiseli zomhlaza ekukhuleni.ALK InhibitorsI-Anaplastic Lymphoma Kinase (ALK) inhibitors isetyenziselwa izigulane ezine-rearrangements ze-ALK zisetyenziselwa izigulane ezine-ALK. I-ALK inhibitors eqhelekileyo iquka: I-Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori)La mayeza avimba iprotheni ye-ALK, ukunciphisa okanye ukumisa ukukhula komhlaza.Olunye unyango olujoliswe kuyoEzinye iithagethi ziquka i-ROS1, i-BRAF, i-MET, i-NTRK, kunye ne-RET. I-oncologist yakho iya kugqiba ukuba umhlaza wakho unazo naziphi na kwezi ziguquko.ImmunotherapyImmunotherapy amayeza anceda amajoni akho omzimba aqaphele kwaye ahlasele iiseli zomhlaza. Olu nyango luhlala lusetyenziswa njengokhetho lonyango lokuqala unyango lomhlaza wemiphunga we-metastatic olungelulo oluncinci.PD-1 kunye ne-PD-L1 InhibitorsLa machiza avimba i-PD-1 (iprotheni yokufa kweeseli ezicwangcisiweyo 1) okanye i-PD-L1 (iiprotheni ezicwangcisiweyo ze-cell ligand 1), ezinceda iiseli zomhlaza ukuba ziphephe amajoni omzimba. I-PD-1 eqhelekileyo kunye ne-PD-L1 inhibitors ziquka: i-Pembrolizumab (Keytruda) i-Nivolumab (Opdivo) i-Atezolizumab (Tecentriq) i-Durvalumab (Imfinzi) - idla ngokusetyenziswa emva kwe-chemoradiation kwinqanaba le-III NSCLC.La machiza angasetyenziswa yedwa okanye adityaniswe ne-chemotherapy.CTLA-4 block Iprotheni ye-T-lymphocyte ehambelana ne-4) iprotheni, ekwanceda iiseli zomhlaza ukuba ziphephe amajoni omzimba. I-Ipilimumab (Yervoy) yinto eqhelekileyo ye-CTLA-4 inhibitor, ngamanye amaxesha isetyenziswe ngokudibanisa ne-PD-1 inhibitors. Iziyobisi ze-ChemotherapyChemotherapy zisebenzisa iikhemikhali ezinamandla zokubulala iiseli zomhlaza. Nangona iindlela zonyango ezijoliswe kuzo kunye ne-immunotherapies ziye zaxhaphaka kakhulu, i-chemotherapy ihlala iyindlela yonyango esemgangathweni, ngakumbi ngokudibanisa nolunye unyango. Amachiza aqhelekileyo echemotherapy asetyenziselwa unyango lomhlaza wemiphunga we-metastatic olungelulo oluncinci zibandakanya: Amachiza asekelwe kwiPlatinum (iCisplatin, Carboplatin) I-Taxanes (i-Paclitaxel, i-Docetaxel) i-Pemetrexed (i-Alimta) i-Gemcitabine (i-Gemzar) Unyango lwe-Radiation TherapyRadiation therapy isebenzisa imitha ephezulu yamandla ukubulala iiseli zomhlaza. Ihlala isetyenziselwa ukuthomalalisa iimpawu ezinje ngeentlungu okanye ukuphelelwa ngumoya xa umhlaza usasazeke kwiindawo ezithile ezifana nethambo okanye ingqondo. Isenokusetyenziswa ukunyanga ithumba emiphungeni engundoqo.UtyandoUqhaqho alulolona nyango luphambili unyango lomhlaza wemiphunga we-metastatic olungelulo oluncinci, kodwa inokusetyenziswa kwiimeko ezithile ukususa i-metastasis enye, ngakumbi kwingqondo okanye kwi-adrenal glands. Oku kudla ngokuba yinxalenye yesicwangciso sonyango olubanzi.Uvavanyo lwezonyango Ulingo lwezonyango luphononongo lophando oluvavanya unyango olutsha lomhlaza. Banikezela ngezigulane ukufikelela kunyango oluphambili olungekafumaneki ngokubanzi. Cinga ngokuxoxa ngeendlela zolingo lwezonyango kunye nogqirha wakho. I-Shandong Baofa Cancer Research Institute ithatha inxaxheba ngokukhutheleyo kwaye ikhuthaza uphando lwezonyango.Ukulawula iziphumo ebezingalindelekanga Unyango lomhlaza lunokubangela iziphumo ebezingalindelekanga. Ugqirha wakho unokukunceda ukulawula ezi ziphumo ebezingalindelekanga ngamayeza kunye nolunye ukhathalelo oluxhasayo. Iziphumo ebezingalindelekanga eziqhelekileyo ziquka ukudinwa, isicaphucaphu, iintlungu, nokulahleka kweenwele. Kubalulekile ukunxibelelana nazo naziphi na iziphumo ebezingalindelekanga ozifumana kwiqela lakho lezempilo. unyango lomhlaza wemiphunga we-metastatic olungelulo oluncinci iyahluka ngokuxhomekeke kwizinto eziliqela, kuquka inqanaba lomhlaza, impilo yesigulana iyonke, kunye nonyango oluthile olufunyenweyo. Nangona isifo sihlala sihamba phambili, amazinga okusinda aphuculwe kakhulu ngokuphuhliswa konyango olutsha. Xoxa nge-prognosis yakho kunye ne-oncologist yakho.I-Palliative CarePalliative Care igxile ekudambiseni iimpawu kunye nokuphucula umgangatho wobomi kwizigulana ezinezigulo ezimandundu, kubandakanywa nomhlaza wemiphunga we-metastatic. Inokubonelelwa nakweliphi na inqanaba lesi sifo, kwaye ihlala isetyenziswa kunye nolunye unyango. Ukhathalelo lwePalliative lunokunceda ukulawula iintlungu, ukuphelelwa ngumphefumlo, ukudinwa, kunye nezinye iimpawu.Iingqwalasela ezingundoqo kwiZiGqibo zoNyangoUkukhetha unyango olululo unyango lomhlaza wemiphunga we-metastatic olungelulo oluncinci sisigqibo esinzima ekufuneka senziwe ngokubonisana nooncologist wakho. Nantsi eminye imiba ephambili: Iziphumo zoVavanyo lweMolekyuli: Ukuqonda utshintsho oluthile lwemfuza okanye i-biomarkers kwiiseli zakho zomhlaza kubalulekile ekumiseleni ukuba ngaba unyango olujoliswe kuyo lulolo khetho. Impilo iyonke: Impilo yakho iyonke kunye nenqanaba lokuqina liya kuba nefuthe loluphi unyango olufanelekileyo. Iinjongo zonyango: Xoxa ngeenjongo zakho zonyango nogqirha wakho, nokuba kukwandisa ixesha lokuphila, ukuphucula umgangatho wobomi, okanye zombini. Iziphumo ebezingalindelekanga: Qonda iziphumo ebezingalindelekanga zokhetho ngalunye lonyango kunye nendlela enokulawulwa ngayo. Uvavanyo lweklinikhi: Cinga ukuba ingaba ukuthatha inxaxheba kulingo lwezonyango kukulungele na.INtubeko zakutsha nje kuNyango loMhlaza weMiphungaUmmandla wonyango lomhlaza wemiphunga uvela ngokukhawuleza. Unyango olutsha kunye neendlela zihlala ziphuhliswa. Ezinye zenkqubela phambili zamva nje ziquka: I-antibody-drug conjugates (ADCs): La machiza adibanisa uhlobo oluthile lonyango olujoliswe kuyo kunye namandla okubulala iiseli e-chemotherapy. Ii-antibodies ezikhethekileyo: Ezi zilwa-buhlungu zibandakanya iiseli zokhuselo lomzimba ukuba zijolise kwaye zibulale iiseli zomhlaza. Ubuchwephesha obuphuculweyo bokusasazeka kwemitha: Ubuchwephesha obunjengonyango lwemitha yemitha ye-stereotactic yomzimba (SBRT) ihambisa iidosi eziphezulu zokusasazeka kwemitha kumathumba ngelixa unciphisa umonakalo kwizihlunu ezingqongileyo. unyango lomhlaza wemiphunga we-metastatic olungelulo oluncinci kunokuba ngumngeni, kodwa zininzi izixhobo ezifumanekayo zokunceda izigulane kunye neentsapho zazo. Amaqela enkxaso, iingcebiso, kunye noluntu lwe-intanethi lunokubonelela ngenkxaso yeemvakalelo kunye neengcebiso ezisebenzayo. Ukugcina impilo esempilweni, kuquka ukutya okunesondlo nokuzilolonga rhoqo, nako kunokuphucula umgangatho wobomi. I-Disclaimer: Olu lwazi lujoliswe kulwazi ngokubanzi kunye neenjongo zolwazi kuphela, kwaye aluquki iingcebiso zonyango. Kubalulekile ukudibana nengcali yokhathalelo lwempilo kuyo nayiphi na inkxalabo yezempilo okanye ngaphambi kokuba wenze naziphi na izigqibo ezinxulumene nempilo yakho okanye unyango.Izixhobo zangaphandle:Umbutho woMhlaza waseMelika-Ukunyanga uMhlaza weMiphunga yeSeli engeNcinci ngeSigabaCancer.Net - Umhlaza wemiphunga - Iseli engeyincinci - Iinketho zonyangoNational Comprehensive Cancer Network (NCCN) - Non-Small Cell Lung Cancer Guidelines for Patients (PDF)IiReferensi: Idata kunye nolwazi olunikiweyo lusekwe kulwazi lwangoku lwezonyango kwaye lufunyenwe kwimibutho ethembekileyo yezonyango ukusukela nge-26 kaOkthobha 2023.